The restructuring follows the company’s receipt of a letter from the FDA citing “deficiencies” in its approval application for diabetes drug Zynquista.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,